Last Update

This profile was last updated on 8/14/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong David Hallal?

David L. Hallal

Chief Executive Officer

Alexion Pharmaceuticals Inc

HQ Phone:  (203) 272-2596

Direct Phone: (203) ***-****direct phone


+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.


  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Alexion Pharmaceuticals Inc

100 College Street

New Haven, Connecticut,06510

United States

Company Description

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion is the global leader in complement inhibition and has developed and commercializes the firs...more

Background Information

Employment History

Vice President of Sales

Eyetech Pharmaceuticals , Inc.


PhRMA companies

Board Member

Biotechnology Industry Organization

Board Member



University of New Hampshire

Web References(136 Total References)

Experience Matters to Chart a Roadmap for Transformative Therapies - Scholar RockScholar Rock

www.scholarrock.com [cached]

Today, Scholar Rock has tapped the skill of an experienced navigator, David Hallal, to help us pave the path for SRK-015 in SMA and other neuromuscular diseases, along with our growing pipeline of innovative medicines in earlier stages (see press release).
Over the past two decades, David is a leader who has brought first-in-class medicines to market and onto achieving blockbuster status: Soliris, Stensiq, Kanuma, Macugen, Amevive, Epogen, Neupogen, Neulasta and Aranesp. He has been a pioneer and innovator in developing the roadmaps for these products, through all the challenges along the path of bringing them to patients: clinical trial design; FDA, EMA, and PMDA approvals; pricing and reimbursement; and global infrastructure for commercialization. In the case of the companies on his resume, David started on the ground floor, building the commercial foundation for the company and each product's position in the market. He joined Eyetech when they had 150 employees and preparing to file and launch Macugen as a bold, new anti-VEGF treatment for age-related macular degeneration. And he joined Amgen when they had 1,000 employees and were on a steep multi-product growth trajectory. When David joined Alexion in 2006, they had less than 300 employees and were anticipating the filing, approval, and launch of Soliris®, and he was handed the responsibility to build a U.S. and then international commercial platform for Soliris, leading to a $3 billion product franchise and made a difference in the lives of patients with two ultra-rare diseases. That experience will undoubtedly be an invaluable asset for Scholar Rock and serve us well on the road ahead with our innovative medicines. David has precisely the type of experience that a startup like ours needs, particularly for a promising new treatment for a rare disease, like our SRK-015 for SMA. At Scholar Rock, we will continue to bring together the expert minds and a passionate team to develop SRK-015 and additional medicines. Having travelled before on the frontier of commercializing new medicines, people like David Hallal can help lead the way.

Board of Directors - Scholar RockScholar Rock

www.scholarrock.com [cached]

David Hallal
Chairman of the Board of Directors, Scholar Rock® Former Chief Executive Officer, Alexion Pharmaceuticals Mr. Hallal has served as our Chairman since July 2017 and has nearly 30 years of experience building and leading organizations to develop and commercialize therapies for patients with severe and life-threatening conditions, including rare diseases. Most recently, Mr. Hallal spent more than ten years at Alexion Pharmaceuticals, Inc. in executive positions and played a central role in transforming the company from the pre-commercial stage in 2006 to greater than $3 billion in annual revenues by 2016. As the Chief Executive Officer of Alexion, Mr. Hallal transitioned the company from a single-product to a multi-product enterprise, including his most recent product development milestones of the highly successful launch of Strensiq® and the rapid advancement of Alexion's highest value pipeline candidates form a preclinical stage to registration trials in multiple diseases in just 18 months. Prior to his appointment as CEO, Mr. Hallal served as Alexion's Chief Operating Officer and then Chief Commercial Officer, where he built the company's commercial infrastructure and a 50-country operating platform which launched Soliris® for two ultra-rare diseases, Paroxysmal Nocturnal Hemoglobinuria and atypical Hemolytic Uremic Syndrome, resulting in the most successful commercialization of an ultra-orphan drug in the biotechnology industry. Prior to Alexion, Mr. Hallal held commercial leadership positions at biopharmaceutical companies where he launched and expanded the adoption of numerous first-in-class and blockbuster products in hematology, oncology, nephrology, immunology and ophthalmology. At OSI Eyetech, he was Vice President of Sales where he led the U.S. launch of Macugen®, a first-in-class anti-VEGF therapy for the treatment of age-related macular degeneration. At Biogen, he led the immunology sales team, where he built the sales organization to launch Amevive®, a first-in-class biologic for psoriasis. For more than ten years starting in 1992, Mr. Hallal held various leadership roles at Amgen focused on the major oncology and hematology products Epogen®, Neupogen®, Neulasta® and Aranesp®. Mr. Hallal holds a BA in psychology from the University of New Hampshire.

Newsroom: Press Releases and Media Materials | Alexion, Rare Disease Leader

www.alexionpharma.com [cached]

David Hallal Becomes Chief Executive Officer of Alexion
On April 1, 2015, David Hallal assumed the role of Chief Executive Officer of Alexion.


David Hallal
Chief Executive Officer Alexion Pharmaceuticals, Inc. Read More

Featured Stories: Alexion Recognizes Rare Disease Day 2016 | Alexion, Rare Disease Leader

alexionpharma.com [cached]

Today serves as a special milestone for Alexion as we celebrate Rare Disease Day by dedicating our new global headquarters in New Haven to the patients who inspire us every day to work with a sense of urgency to deliver medical breakthroughs where none currently exist," said David Hallal, Chief Executive Officer of Alexion.
"Alexion's 3,000 employees around the world will participate in activities that demonstrate our commitment to transform lives and create lasting impact for the patients and families we serve today, and the generations that follow." CEO David Hallal, Leonard Bell, Commissioner Catherine Smith, Mayor Toni Harp, Congresswoman Rosa Delauro, Senator Blumenthal, Senator Murphy, Yale University President Peter Salovey, and CFGNH Will Ginsberg at Alexion's Ribbon Cutting Ceremony on Rare Disease Day 2016

Similar Profiles


Browse ZoomInfo's Business
Contact Directory by City


Browse ZoomInfo's
Business People Directory


Browse ZoomInfo's
Advanced Company Directory